Effect of Protocolized Magnesium Replacement on Mortality and Atrial Fibrillation in Critically Ill Patients

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

3,253

Participants

Timeline

Start Date

November 1, 2025

Primary Completion Date

March 1, 2027

Study Completion Date

June 1, 2027

Conditions
Critical Illness
Interventions
DRUG

Magnesium sulfate administration

Magnesium sulfate is used in both arms for magnesium replacement.

DRUG

Magnesium oxide

In the higher-target arm, magnesium oxide 420mg po q12h x 2 is one of the options available for magnesium replacement when magnesium levels lie between 0.75 and 0.95mmol/L.

DRUG

Magnesium glucoheptonate

Magnesium glucoheptonate 30mL po q12h x 2 is an oral option for magnesium replacement in the higher-target arm.

Trial Locations (5)

L1S 2J4

Lakeridge Health Ajax-Pickering, Ajax

L1G 8A2

Lakeridge Health Oshawa, Oshawa

M1E 4B9

Scarborough Centenary Hospital, Toronto

M1P2V5

Scarborough General Hospital, Toronto

M1W 3W3

Scarborough Birchmount Hospital, Toronto

All Listed Sponsors
collaborator

Scarborough Health Network

UNKNOWN

collaborator

Lakeridge Health Corporation

OTHER

lead

Scarborough General Hospital

OTHER